Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Journal for ImmunoTherapy of Cancer, 2019 Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith +40 more
doaj +1 more source
The alarmin IL33 orchestrates type 2 immune-mediated control of thymus regeneration
Nature Communications, 2023 As the primary site of T-cell development, the thymus dictates immune competency of the host. The rates of thymus function are not constant, and thymus regeneration is essential to restore new T-cell production following tissue damage from environmental ...
Emilie J. Cosway +7 more
doaj +1 more source
Immunotherapy of lung cancer: An update [PDF]
, 2006 In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Aman MJ +36 more
core +1 more source
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
OncoImmunology, 2023 BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory ...
Maite Alvarez +16 more
doaj +1 more source
The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. [PDF]
, 2020 The role of palliative surgery in the management of acute complications in patients with disseminated malignancy remains controversial given the complexity of assessing acute surgical risk and long-term oncologic outcome. With the emergence of checkpoint
Bold, Richard J +13 more
core
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]
, 2019 Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence +2 more
core +2 more sources
OncoImmunology, 2018 Memory CD8+ T cell responses have the potential to mediate long-lasting protection against cancers. Resident memory CD8+ T (Trm) cells stably reside in non-lymphoid tissues and mediate superior innate and adaptive immunity against pathogens.
Felipe Gálvez-Cancino +13 more
doaj +1 more source
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Genome Medicine, 2018 For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies.
Samantha L. Bucktrout +2 more
doaj +1 more source
Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity
Frontiers in Oncology, 2021 Although abscopal tumor regression remains a rare phenomenon, interest in exploiting how radiation stimulates the immune system to induce systemic abscopal response is increasing.
Jin-Zhi Lai +7 more
doaj +1 more source
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]
, 2004 Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core +1 more source